Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 697-702

  Ruccione, Kathleen S ^a   Mudambi, Kiran ^a   Sposto, Richard ^a   Fridey, Joy ^a   Ghazarossian, Suzy ^a   Freyer, David R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Blood transfusions; Childhood cancer; Iron overload

Indexed keywords

HEMOGLOBIN; IRON;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; ERYTHROCYTE TRANSFUSION; EWING SARCOMA; FEMALE; GERM CELL TUMOR; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NEPHROBLASTOMA; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD;

ADOLESCENT; ANEMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; INFANT; IRON OVERLOAD; MALE; NEOPLASMS; SURVIVORS; YOUNG ADULT;

EID: 84864928828     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24046     Document Type: Article

References (28)

1. Barnard DR, Rogers ZR. Blood component therapy. In: Altman AJ, editor. Supportive care of children with cancer: Current Therapy and Guidelines from the Children's Oncology Group. 2004. Baltimore: The Johns Hopkins University Press; pp. 39-57.
2. Hastings CA, Lubin BH, Feusner J. Hematologic supportive care for children with cancer. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 2005. Philadelphia: Lippincott Williams & Wilkins; pp. 1231-1268.
3. Buchanon GR. Commentary Blood transfusions in children with cancer and hematologic disorders: Why, when, and how? Pediatr Blood Cancer 2005; 44: 114-116.
4. Kohgo Y, Ikuta K, Ohtake T, et al. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008; 88: 7-15.
5. Blair AB, Tarango C, Bowers D, et al Transfusional iron overload in acute lymphoblastic leukemia. In: American society of pediatric hematology oncology 2009. San Diego, CA. Available at: http://aspho.confex.com/aspho/2009/webprogram/Paper2161.html (Accessed December 4, 2011).
6. Jastaniah W, Harmatz P, Pakbaz Z, et al. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer 2008; 50: 319-324.
7. Lutz K, von Komorowski, Durken M, et al. Myocardial iron overload in transfusion-dependent pediatric patients with acute leukemia. Pediatr Blood Cancer 2008; 51: 691-693.
8. Nelson SC, Bendel AE, Perkins JL. Transfusional iron overload in pediatric oncology. In: American society of pediatric hematology/oncology abstracts. 2007. Toronto, Canada: Pediatric Blood & Cancer.
9. Halonen P, Mattila J, Suominen P, et al. Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters. Pediatrics 2003; 111: 91-96.
10. Vag T, Kentouche K, Krumbein I, et al. Noninvasive measurement of liver iron concentration at MRI in children with acute leukemia: Initial results. Pediatr Radiol 2011; 41: 980-984.
11. Eng J, Fish JD. Insidious iron burden in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56: 368-371.
12. Reddy K, Eng J, Carlson C, et al. Impact of transfusional support for childhood cancer: Peering behind the iron curtain. Pediatr Blood Cancer 2011; 56: 908.
13. Rosoff SD, editor. Pediatric transfusion: A physician's handbook, 1st edition. Bethesda, MD. American Association of Blood Banks; 2003.
14. Werba BE, Hobbie W, Kazak AE, et al. Classifying the intensity of pediatric cancer treatment protocols: The intensity of treatment rating scale 2.0 (ITR-2). Pediatr Blood Cancer 2007; 48: 673-677.
15. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343: 327-331.
16. Gordeuk VR, Bacon BR, Brittenham GM. Iron overload: Causes and consequences. Annu Rev Nutr 1987; 7: 485-508.
17. Brittenham GM, Sheth S, Allen CJ, et al. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 2001; 38: 37-56.
18. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239-252.
19. Link G, Tirosh R, Pinson A, et al. Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 1996; 127: 272-278.
20. Panjrath GS, Patel V, Valdiviezo CI, et al. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol 2007; 49: 2457-2464.
21. Minotti G, Ronchi R, Salvatorelli E, et al. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 2001; 61: 8422-8428.
22. Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: Inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 2003; 63: 849-861.
23. Anderson B. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Pediatr Blood Cancer 2005; 44: 584-588.
24. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 2005; 68: 261-271.
25. Kwok JC, Richardson DR. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: Studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol Pharmacol 2004; 65: 181-195.
26. Scottish Intercollegiate Guidelines Network. Long-Term Follow-up of Survivors of Childhood Cancer (Guideline No. 76). 2004 [cited 2011 July 21]; Available from: http://www.sign.ac.uk/pdf/sign76.pdf.
27. Skinner R, Wallace WHB, Levitt GA. Therapy-Based Long Term Follow Up Practice Statement. 2005 [cited 2011 July 21]; 2nd: Available from: http://www.cclg.org.uk/researchandtreatment/content.php?3id=29&2id=19.
28. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22: 4979-4990.